Werewolf Therapeutics (HOWL) Current Deferred Revenue (2022 - 2024)
Werewolf Therapeutics (HOWL) posted quarterly Current Deferred Revenue of $933000.0 for Q1 2024, down 30.37% on a QoQ basis from $1.3 million in Q4 2023.
Werewolf Therapeutics (HOWL) Current Deferred Revenue (2022 - 2024) Analysis & Trends
Werewolf Therapeutics has reported Current Deferred Revenue for 3 years, with the latest figure at $933000.0 in Q1 2024.
- Current Deferred Revenue for Q1 2024 came in at $933000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2024 was $933000.0 (changed N/A YoY), and the FY2023 annual result was $1.3 million, down 82.51% from the prior year.
- Current Deferred Revenue slipped to $933000.0 in Q1 2024, from $1.3 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $7.7 million in Q4 2022 and troughed at $933000.0 in Q1 2024.
- A 3-year average of $2.9 million and a median of $2.4 million in 2023 frame the typical range for Current Deferred Revenue.
- The largest YoY upside for Current Deferred Revenue was 82.51% in 2023 against a maximum downside of 82.51% in 2023.
- A 3-year view of Current Deferred Revenue shows it stood at $7.7 million in 2022, then slumped by 82.51% to $1.3 million in 2023, then slumped by 30.37% to $933000.0 in 2024.
- Per Business Quant data, the three most recent Current Deferred Revenue figures were $933000.0 in Q1 2024, $1.3 million in Q4 2023, and $2.4 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Werewolf Therapeutics | 43.94 Mn | 43.94 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 933,000.00 |
| Dec 31, 2023 | 907,000.00 |
| Sep 30, 2023 | 2.40 Mn |
| Jun 30, 2023 | 2.39 Mn |
| Dec 31, 2022 | 7.66 Mn |